Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2018 shares
Document And Entity Information
Entity Registrant Name	Tiziana Life Sciences plc
Entity Central Index Key	0001723069
Trading Symbol	TLSA
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	136,463,818

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 5,304	$ 64
Prepayments and other receivables	1,609	2,384
Total current assets	6,913	2,448
Property and Equipment, net	7	23
Total non-current assets	7	23
Total assets	6,920	2,471
Current liabilities:
Accounts payable and accrued expenses	6,401	4,749
Total current liabilities	6,401	4,749
Total liabilities	6,401	4,749
Shareholders' Equity:
Called up share capital	8,592	8,141
Share premium	40,862	31,284
Share based payment reserve - Options	3,854	3,213
Share based payment reserve - warrants	743	579
Convertible loan note reserve
Merger relief reserve
Other reserve	(46,171)	(46,171)
Translation reserve	1,977	1,997
Capital reduction reserve	41,292	41,292
Retained earnings	(50,630)	(42,613)
Total shareholders' equity	519	(2,278)
Total liabilities and shareholders' equity	$ 6,920	$ 2,471

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Profit or loss [abstract]
Revenue
Cost of revenue
Gross Profit
Operating expenses:
Research and Development	(5,510)	(6,015)	(4,007)
Operating Expenses	(4,417)	(4,601)	(5,872)
Total operating expenses	(9,927)	(10,616)	(9,879)
Loss from operations	(9,927)	(10,616)	(9,879)
Other income/(expense):
Finance Income/(expense)	(12)	(12)	(12)
Loss from operations before income taxes	(9,939)	(10,628)	(9,891)
Income tax provision	1,945	1,912	121
Loss for the year	(7,994)	(8,716)	(9,770)
Other Comprehensive loss:
Currency translation	(20)	70	650
Comprehensive loss	$ (8,014)	$ (8,646)	$ (9,120)
Basic and diluted loss per share attributable to common shareholders	$ (0.06)	$ (0.09)	$ (0.11)

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Issued Capital	Share Premium	Share Based Payment Reserve (Options)	Share Based Payment Reserve (warrants)	Convertible Loan Note Reserve	Merger Reserve	Other Reserves	Retained Earnings	Capital Redemption Reserve	Translation Reserve	Capital Reduction Reserve	Total
Beginning Balance at Dec. 31, 2015	$ 15,563	$ 33,496	$ 1,503	$ 162	$ 15,510	$ 9,448	$ (46,171)	$ (19,091)		$ 2,121		$ 12,540
Transactions with owners
Issue of share capital	84	546										630
Share based payment (options)			1,144									1,144
Share based payment (warrants)				109								109
Convertible loan note - equity component					1,649			(851)				798
Cancellation of deferred shares	(8,744)								8,744
Capital Reduction		(25,099)				(9,448)			(8,744)		41,292	(1,999)
Prior Year Adjustment								(14)				(14)
Total transactions with owners	(8,660)	(24,553)	1,144	109	1,649	(9,448)		(865)			41,292	(669)
Comprehensive income
Loss for the period								(9,770)				(9,770)
Translation										650		650
Total comprehensive income								(9,770)		650		(9,120)
Ending Balance at Dec. 31, 2016	6,903	8,943	2,647	271	17,158		(46,171)	(29,726)		2,771	41,292	4,088
Transactions with owners
Issue of share capital	84	1,464										1,548
Share based payment (options)			1,324									1,324
Share based payment (warrants)				308								308
Convertible loan note - equity component					419			(419)
Option forfeited in the year			(758)									(758)
Options cancelled in the year								(142)				(142)
Convertible loan note interest					3,610			(3,610)
Convertible Loan Note Conversion	1,154	20,877			(21,188)					(844)
Total transactions with owners	1,237	22,341	566	308	(17,158)			(4,171)		(844)		2,280
Comprehensive income
Loss for the period								(8,716)				(8,716)
Translation										70		70
Total comprehensive income								(8,716)		70		(8,646)
Ending Balance at Dec. 31, 2017	8,141	31,284	3,213	579			(46,171)	(42,613)		1,997	41,292	(2,278)
Transactions with owners
Issue of share capital	451	9,556										10,007
Share based payment (options)			641									641
Share based payment (warrants)				164								164
Capital Reduction												41,300
Convertible loan note interest	1	22						(23)
Total transactions with owners	452	9,578	641	164				(23)				10,812
Comprehensive income
Loss for the period								(7,994)				(7,994)
Translation										(20)		(20)
Total comprehensive income								(7,994)		(20)		(8,014)
Ending Balance at Dec. 31, 2018	$ 8,592	$ 40,862	$ 3,854	$ 743			$ (46,171)	$ (50,630)		$ 1,977	$ 41,292	$ 519

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Loss from operations before income taxes	$ (9,939)	$ (10,628)	$ (9,891)
Adjustments to reconcile net loss to net cash used in operating activities:
Convertible loan interest accrued	12	12	12
Convertible loan interest paid as equity	21
Shares issued in lieu of fees	55
Share based payment - options	672	539	1,257
Cancellation of options		(135)
Share based payment - warrants	171	294	121
Net (increase)/decrease in operating assets/other receivables	(180)	54	121
Net increase/(decrease) in operating liabilities /other liabilities	2,123	2,304	1,174
Depreciation	16	13	11
Loss on foreign exchange	(296)	45	214
Lease adjustment	3	(31)	55
Cash inflow from taxation	2,791
Net cash used in operating activities	(4,551)	(7,533)	(6,926)
CASH FLOWS FROM INVESTING ACTIVITIES
PPE		(1)	(48)
Acquisition of other investments			(294)
Net cash used in investing activities		(1)	(342)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of ordinary shares	9,917	1,542	614
Proceeds from issuance of convertible loan notes			961
Proceeds from issuance of warrants	1,509
Fundraising cost	(1,385)
Net cash provided by financing activities	10,041	1,542	1,575
Net increase/(decrease) in cash and cash equivalents	5,490	(5,992)	(5,693)
Cash and cash equivalent, beginning of period	64	5,802	13,128
Exchange difference	(249)	254	(1,633)
Cash and cash equivalent, end of period	$ 5,304	$ 64	$ 5,802

Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies

ACCOUNTING POLICIES

2.	ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been applied consistently to all the years presented unless otherwise stated.

Basis of preparation

The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board, IFRIC interpretations and the Companies Act 2006 as applicable to companies reporting under IFRS. These accounts have been prepared under the historical cost convention.

Going Concern

The Group incurred losses during the year and has net liabilities at the year end.

The Group is in the early stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and immunology. The directors expect the company to incur further losses and to require significant capital expenditure in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully funded clinical trials to date and is in the process of securing additional investment for purposes of continuing to fund their clinical trials moving forward.

The directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation. On the basis of those projections, the directors conclude that the company will be able to meet its liabilities as they fall due for the foreseeable future, and therefore that it is appropriate to prepare the financial statements under the going concern basis of preparation.

However, until and unless the company secures sufficient investment to fund their clinical trials, there is a material uncertainty about the company’s ability to continue as a going concern, and therefore about the applicability of the going concern basis of preparation. The financial statements do not include the adjustments that would be required if the going concern basis of preparation was considered inappropriate.

Basis of consolidation

Subsidiary undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power over the investee to affect the amount of the investor’s return.

The existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated from the date at which control ceases.

Business combination

The consolidated position of the Group is as a result of the reverse acquisition of Alexander David Investments plc by Tiziana Pharma Ltd and the subsequent listing of the Company as Tiziana Life Sciences Plc on 24 April 2014. Tiziana Pharma Limited was incorporated on 4 November 2013 and prepared its first set of financial statements to 31 December 2014. Therefore, the parent and subsidiary had the same reporting date but Tiziana Pharma Limited had a long period of account. No adjustment was made in the consolidated financial statements for the difference in length of reporting period because the only transaction in Tiziana Pharma Limited at 31 December 2013 was the issue of ordinary share capital of £1.

Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and assess the performance of the segments. The Board considers there to be only one operating segment being the research and development of biotechnological and pharmaceutical products.

Taxation

The tax expense for a period represents the total of current taxation and deferred taxation. The charges in respect of current taxation are based on the estimated taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability for the year is calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.

Foreign currency translation

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group’s presentation currency.

Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.

The financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis:

●

Assets and liabilities at the rate of exchange ruling at the year-end date.

●

Profit and loss account items at the average rate of exchange for the year.

Exchange differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.

License fees

Payments related to the acquisition of rights to a product or technology are capitalized as intangible assets if it is probable that future economic benefits from the asset will flow to the entity and the cost of the asset can be reliably measured.

Payments made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. Where fees related to research and development projects are recognized as an expense in the income statement, due to the uncertainty in the length of time that the Group will hold them the expense is recognized fully at the point of recognition.

Research and development

All on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the development of the Group’s products, the criteria for development costs to be recognized as an asset, as set out in IAS 38 ‘Intangible Assets’, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow to the Group. The Group currently has no qualifying expenditure.

Financial instruments

Financial assets

The Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument.

The Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified separately as financial assets, financial liabilities or equity instruments.

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

(a)

Financial assets, initial recognition and measurement and subsequent measurement

All financial assets not recorded at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs. Financial assets carried at fair value through profit or loss are initially recognized at fair value, and transaction costs are expensed in the income statement. The measurement of financial assets depends on their classification. Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance. The Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income.

(b)

Financial liabilities, initial recognition and measurement and subsequent measurement

Financial liabilities are classified as measured at amortized cost or FVTPL.

A financial liability is classified as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.

The Group’s financial liabilities include trade and other payables.

Share capital

Ordinary shares of the company are classified as equity.

Property, IT and equipment

(i)

Recognition and measurement

Items of property, IT and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment.

When parts of an item of property, IT and equipment have different useful lives, they are accounted for as separate items (major components) of property, IT and equipment.

Gains and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the revaluation reserve are transferred to retained earnings.

(ii)

Depreciation

Depreciation is calculated on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.

Depreciation is recognized in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, IT and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the company will obtain ownership by the end of the lease term.

The estimated useful lives for the current period and the comparative period are as follows.

IT and equipment	3 years
Fixtures and fittings	5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the income statement.

Impairment

Impairment of financial assets measured at amortised cost

At each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.

In establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified approach, depending on the nature of the underlying group of financial assets.

General approach

The general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted cash and cash and cash equivalents.

Under the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognised at an amount equal to the lifetime expected credit losses.

Simplified approach

The simplified approach is applied to the impairment assessment of trade receivables.

Under the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.

Non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Non-financial assets are impaired when its carrying amount exceed its recoverable amount. The recoverable amount is measured as the higher of fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value.

Operating leases

Payments made under operating leases are recognized in profit and loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease.

Share based payments

The calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the company’s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of the awards.

Where employees, directors or advisers are rewarded using share based payments, the fair value of the employees’, directors’ or advisers’ services are determined by reference to the fair value of the share options / warrants awarded. Their value is appraised at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets). Warrants issued in association with the issue of Convertible Loan Notes are also considered as share based payments and a share based payment charge is calculated for these too.

In accordance with IFRS 2, a charge is made to the Statement of Comprehensive Income for all share-based payments including share options based upon the fair value of the instrument used. A corresponding credit is made to a Share Based Payment Reserve, in the case of options/warrants awarded to employees, directors, advisers, and other consultants.

If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options / warrants expected to vest. Non market vesting conditions are included in assumptions about the number of options / warrants that are expected to become exercisable.

Estimates are subsequently revised, if there is any indication that the number of share options / warrants expected to vest differs from previous estimates. No adjustment is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally estimated. Exercise of share options / warrants, the proceeds received are allocated to share capital with any excess being recorded as share premium.

Where share options are cancelled, this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services received over the remainder of the vesting period is recognized immediately within the Statement of Comprehensive Income.

All goods and services received in exchange for the grant of any share based payment are measured at their fair value.

Convertible loan notes

Under IAS 32 the liability and equity components of convertible loan notes must be presented separately on the Statement of Financial Position. The Group has examined the terms of each issue of convertible loan notes and determined their accounting treatment accordingly. Convertible loan notes are treated differently depending upon a number of factors.

Where there is no option to repay as cash and the interest rate is fixed

The Group considers these to be Convertible Equity Instruments and records the principal of the loan note as an equity in a Convertible loan note reserve. The accrued interest on the principal amount, for which there is no obligation to settle in cash, is also recorded in the Convertible loan note reserve. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the convertible loan note reserve to share capital and share premium.

Where there is no option to repay as cash and the interest rate is variable

The Group considers these to be Convertible Debt Instruments and records the principal of the loan note as a debt liability in the liabilities section of the balance sheet. The accrued interest on the principal amount is recorded in the income statement and as an increase in the debt liability. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the debt liability to share capital and share premium.

Critical Accounting Estimates and Judgements

12 Months Ended

Dec. 31, 2018

Critical Accounting Estimates And Judgements

CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

3.	CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being International Financial Reporting Standards as adopted by the European Union, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities, income and expenditure and the disclosures made in the financial statements. Such estimates and judgements must be continually evaluated based on historical experience and other factors, including expectations of future events.

When entering into agreements with third parties which provide the rights to conduct research into specific biological processes the group account for these agreements as an expense if the agreements are ‘milestone’ in nature and relate to the Group’s own research and development costs. Such agreements involve periodic payments and are evaluated as representing payments made to fund research.

The only other critical accounting estimates and judgements in the preparation of the financial statements were fair value estimates used in the calculation of share based payments and warrants which have been detailed above in note 2, accounting policies, and note 16, share based payments, to the accounts.

The Group has also made a judgement on the impact of Brexit during the preparation of the financial statements and considered it to not be significant.

Remuneration of Key Management Personnel

12 Months Ended

Dec. 31, 2018

Remuneration Of Key Management Personnel

REMUNERATION OF KEY MANAGEMENT PERSONNEL

REMUNERATION OF KEY MANAGEMENT PERSONNEL

	Year ended December 31,
$’000	2018				2017				2016
	Directors fees		Salary		Directors fees		Salary		Directors fees		Salary

W Simon		51				49				52		-
G. Cerrone		124				86				108		-
R. Dalla-Favera		26				26				27		-
K. Shailubhai (1)		-		300		10		286		27		-
		201		300		171		286		214		-

(1)

Kunwar Shailubhai became an employee of the company on May 24, 2017, at which point he ceased to be a non-executive director.

The following share options were granted to directors in the following periods:

	Year ended December 31,
	2018		2017		2016
	Number of options		Number of options		Number of options

G. Cerrone		550,000		-		3,259,403
K. Shailubhai		6,500,000		400,000		-
L. Zanbeletti		550,000
		7,600,000		400,000		3,259,403

The key management personnel of the Group are considered to be represented by the directors and officers of the company.

No director has yet benefitted from any increase in the value of share capital since issuance of the options.

No director exercised share options in the year.

For the year ended December 31, 2017, the company made $17k (2017: $6k; 2016: $0k) of payments to defined contribution pension schemes on behalf of directors or employees.

Taxation

12 Months Ended

Dec. 31, 2018

Taxation [Abstract]

TAXATION

9.	TAXATION

	Year Ended December 31,
	2018 $’000			2017 $’000			2016 $’000
Group
Current year tax (credit)		(1,067	)		(489	)		-
Adjustments due to prior periods		(879	)		(1,423	)		(121	)
Total tax (credit) for the period		(1,945	)		(1,912	)		(121	)

The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as follows:
Loss before taxation		(9,939	)		(10,628	)		(9,770	)
Loss charged at standard rate of corporation tax 19 % (2017: 19.25%; 2016: 20%)		(1,888	)		(2,046	)		(1,953	)
Other timing differences		1,104			2,889			1,656
Expenses not deductible for taxation		176			31			297
Adjustments due to prior periods		(879	)		(1,423	)		(121	)
Research and development claim		(459	)		(1,366	)		-
Other timing differences					3			-
		(1,945	)		(1,912	)		(121	)

The Research and Development claim has been calculated in accordance with the R&D tax relief available to small and medium sized entities, whereby the entity is able to claim a cash tax credit (if loss making), worth up to 14.5% of the surrenderable losses.

The adjustments due to prior periods relates to R&D tax relief claims or the years ended December 31, 2017, 2016 and 2015. In prior periods there was not enough certainty to recognize an asset for these claims. Under UK tax legislation, a 2 year window is available under which R&D tax relief can be claimed.

No deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will be recoverable.

The amount of tax losses for which no deferred tax assets has been recognized for the year ended December 31, 2018 is $3,928 (2017; $4,738; 2016: $3,535).

Loss Per Share

12 Months Ended

Dec. 31, 2018

Loss Per Share

LOSS PER SHARE

10.

LOSS PER SHARE

Basic loss per share is calculated by dividing the profit attributable to equity holders of the company by the weighted average number of ordinary shares in issue during the year.

	Year ended December 31,
	2018			2017			2016

(Loss) attributable to equity holders of the company ($000)		(7,994	)		(9,135	)		(10,622	)
Weighted average number of ordinary shares in issue		127,553,866			106,403,903			93,592,195
Basic loss per share (cents per share)		(6.27	)		(8.59	)		(11.35	)

As the Group is reporting a loss from continuing operations for the year then, in accordance with IAS 33, the share options are not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented on the face of the income statement are therefore identical. All earnings per share figures presented above arise from continuing and total operations and therefore no earnings per share for discontinued operations are presented.

The earnings have been amended to include the interest accrued on Convertible Loan Notes.

Other Assets

12 Months Ended

Dec. 31, 2018

Other Assets

OTHER ASSETS

13.

OTHER ASSETS

In June 2016, the Board approved the purchase of the Data repository of DNA from SharDNA (an Italian entity in liquidation) for EUR 258,000, approximately $268,000.

Management recognizes that the transaction is not the purchase of a business but the purchase of key assets owned by SharDNA. These assets are to be owned by Tiziana Life Sciences PLC and will be loaned to its subsidiary Longevia SRL for no extra cost.

No research and development work has been carried out to this date, but Management anticipates that this will commence within the next 12 months.

As there is current legal action pending against the liquidators as to the validity to the sale of the assets, the company is unable to utilize these assets until the legal action is resolved. For this reason, the investment has been recognized as a current asset until such a time that the company is able to use this asset. In the event the company is unable to use the asset as a result of the legal action denoted above, the company will receive their money back.

Investments in Subsidiaries

12 Months Ended

Dec. 31, 2018

Disclosure of subsidiaries [abstract]

INVESTMENTS IN SUBSIDIARIES

14.

INVESTMENTS IN SUBSIDIARIES

The company’s interest in subsidiary undertakings is as follows:

Name	Principal activity	Registered Address	Percentage shareholding			Country of incorporation
Tiziana Pharma Limited	Clinical stage biotechnology company	3^rdFloor, 11-12 St James’s Square, London, SW1Y 4LB		100	%	England & Wales
Tiziana Therapeutics, Inc.	Clinical stage biotechnology company	420 Lexington Avenue Suite 2525 New York, NY 10170		100	%	USA
Longevia Genomics SRL	Biotech Discovery Company	Via Constantinpoli 42 09100-Cagliari (CA)		100	%	Italy

Tiziana Therapeutics, Inc. was incorporated on 28 October 2015. This entity was set up to house the company’s US operations.

Longevia Genomics SRL was incorporated on 4 July 2016. This entity was established to enable the company to carry out R&D activities in Sardinia.

Share Capital

12 Months Ended

Dec. 31, 2018

Disclosure of classes of share capital [abstract]

SHARE CAPITAL

15.

SHARE CAPITAL

Company and Group

	2018		2017		2018		2017		2018		2017
	Ordinary Shares				Deferred Shares				£000
In issue at 1 January		125,054,805		94,393,401		-		-		3,752		2,832
Issued for cash		7,742,167		1,301,250		-		-		232		66
Conversion of Convertible Loan notes		-		700,000		-		-		-		854
Conversion of warrants		1,454,644		-		-		-		45		-
Conversion of Loan		2,137,625								65
In lieu of commission		74,577		-		-		-		-		-
In issue at 31 December		136,463,818		125,054,805		-		-		4,094		3,752

Ordinary Shares

Ordinary shares have a par value of £0.03. They entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. The company does not have a limited amount of authorized capital.

Issuance of ordinary shares

In March 2017, a notification was received from warrant holders to exercise warrants over 1,789,524 ordinary shares in the company.

In August 2017, the Board passed a resolution to convert all outstanding Convertible Loan Notes effective from 26 July 2017. It also resolved that the Convertible loan note holders be offered an additional bonus coupon of three years of interest at the relevant applicable rate of return for agreeing to the immediate conversion of the Convertible loan note’s into ordinary shares. The company has issued 28,455,214 new ordinary shares in respect of this conversion. All of the new shares are subject to a restriction on disposal for a period of 12 months.

In November 2017, 283,333 new ordinary shares were issued by way of a further placing of ordinary shares to raise finance.

An additional 133,333 new ordinary shares were issued in December 17 by way of a further placing of ordinary shares to raise finance.

Share issues since 1 January 2018

In January 2018, 166,667 new ordinary shares were issued by way of a placing of ordinary shares to raise finance.

In March 2018, 600,000 new ordinary shares were issued by way of a further placing of ordinary shares to raise finance.

An additional 1,031,250 new ordinary shares were issued in April 2018 by way of a further placing of ordinary shares to raise finance. In addition, 51,563 new ordinary shares were issued to intermediaries in lieu of commissions on the funds raised.

Also in April 2018, 23,014 new ordinary shares were issued in relation to a shortfall in capitalized interest due to a former holder of the Company’s Class C Convertible Loan Notes which was discovered during the annual audit process.

In October 2018, 1,515,150 new ordinary shares were issued by way of a further placing of ordinary shares to raise finance.

In November 2018, 4,429,100 new ordinary shares were issued as part of the initial public offering of American Depositary Shares on the Nasdaq Global Market. In addition to the IPO, 2,137,625 new ordinary shares were issued to extinguish £1.3 million in debt.

In November 2018, notification was also received from warrant holders to exercise warrants over 1,400,644 ordinary shares.

In conjunction with the IPO, the Company resolved to allow the holders of its warrants to exercise at reduced exercise prices in the period ending on 30 November 2018. Notification was also received from warrant holders to exercise warrants over 54,000 ordinary shares in connection with this offer.

Share Based Payments

12 Months Ended

Dec. 31, 2018

Share Based Payments

SHARE BASED PAYMENTS

16.

SHARE BASED PAYMENTS

Group and Company Options

The company operates share-based payment arrangements to remunerate directors and key employees in the form of a share option scheme. The exercise price of the option is normally equal to the market price of an ordinary share in the company at the date of grant.

	2018						2017						2016
	Weighted						Weighted						Weighted
	Average exercise price (cents)			Options (’000)			Average exercise price (cents)			Options (’000)			Average exercise price (cents)		Options (’000)

Outstanding at 1 January		125			10,717			90			12,449			35		7,985
Granted		104			9,500			216			668			190		4,464
Forfeited		(219	)		(1,600	)		(20	)		(2,400	)		-		-

Outstanding at 31 December		107			18,617			125			10,717			90		12,449

Exercisable at 31 December		50			5,236			57			5,011			41		4,152

No options were exercised during the years ended 31st December 2018, 2017 and 2016.

The total outstanding fair value of the share option instruments is deemed to be approximately $6,591 as at December 31, 2018 (2017: $6,217k; 2016: $2,305k).

The Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions below.

Historical volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable to the company.

The company has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.

The company has estimated a forfeiture rate of zero.

	10 March 2017			30 August 2017			30 April 2018

Grant date share price	£	1.725		£	1.595		£	0.8175
Exercise share price	£	1.725		£	1.595		£	0.8175
Vesting periods		Yr1, Yr 2, Yr 3, Yr4			Yr 1, Yr 2, Yr 3, Yr4			Yr1, Yr 2, Yr 3, Yr4

Risk free rate		0.38% to 1.09	%		0.69% to 1.09	%		0.69% to 1.03	%
Expected volatility		80% to 167	%		58% to 60	%		58% to 60	%
Option life		10 years			10 years			10 years

For the options issued with a market condition attached, the Directors have used the Monte Carlo simulation to estimate the fair value of these options, the company uses the following methods to determine its underlying assumptions:

	●	expected volatilities are based on the historical volatilities of the market

	●	the expected term of the awards is 15 years based on managements’ assessment of when the market condition is likely to be achieved

	●	a range of fair values per share were produced and management have determined the most appropriate value based on their knowledge of the market and vesting conditions being fulfilled.

Warrants

The Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model. The total fair value of the warrant instruments is deemed to be approximately $340,501 as at 31 December 2017. For each set of warrants, the charge has been expensed over the vesting period. A share based payment charge for the year to December 31, 2017 of $120,441 (2016: $156,424) has been expensed in the statement of comprehensive income.

The directors estimate the total fair value of warrant instruments at 30 June 2018 is $1,397,662 (unaudited), and the share based payments charge taken to the statement of comprehensive income for the six month period to June 30, 2018 is $89,431 (unaudited).

Convertible Loan Notes

12 Months Ended

Dec. 31, 2018

Convertible Loan Notes

CONVERTIBLE LOAN NOTES

17.

CONVERTIBLE LOAN NOTES

Group and Company

Planwise Convertible Loan Notes 2016

From the date of the reverse acquisition a convertible loan note of $247k was in existence as detailed in the Admission Document dated 31 March 2014. Proceeds of the subscriptions for the notes are to be used exclusively to finance the company’s on-going working capital requirements. The terms of the loan note are that the loan notes, plus accrued interest at a rate of 4 per cent above Bank of England base rate per annum, will convert into ordinary shares in the company at a price of £0.10 per share at the election of Planwise any time after the second anniversary of the readmission to AIM on 24 April 2014. The company considers this to be a Convertible Debt Instrument as detailed in the policy described at note 2.

Accounting for the convertible debt instrument

The net proceeds received from the issue of the Planwise Convertible Loan Note has been recorded as a debt liability in the balance sheet and the accrued interest charged to the income statement and the debt liability. The liability for the convertible debt instrument is;

Planwise Convertible Loan Note

	Year ended December 31,
	2018		2017		2016
	$000		$000		$000
Convertible loan notes issued		290		278		247
Accrued interest		11		12		31

		302		290		278

Reserves

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

RESERVES

18.

RESERVES

The share based payment reserve for warrants represent the value of equity shares which could be issued in future accounting periods if the warrants in issue are exercised.

The share based payment reserve for options represents the value of equity shares which could be issued in future accounting periods if the share based payment options in issue are exercised.

The other reserve was created as a result of the reverse acquisition of Alexander David Investments plc in the year and the accounting treatment required, which is described in Note 2. The reserve is required due to the fact that the reverse acquisition accounting requires the legal parent’s equity structure to be shown.

Retained earnings represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders.

The capital reduction reserve is credited with $41.3m of reserves arising from the court approved capital reduction detailed below. These reserves are designated as realized profits available for distribution under section 830 (2) of the Companies Act 2006.

On September 14, 2016, the High court granted the company permission to cancel its share premium account and its capital redemption reserve. The order had previously been ratified at the AGM held on June 30, 2016.

The company also decided to cancel its merger relief reserve as part of the capital reduction exercise.

Financial Instruments

12 Months Ended

Dec. 31, 2018

Financial Instruments

FINANCIAL INSTRUMENTS

19.

FINANCIAL INSTRUMENTS

The main risks arising from the Group’s financial instruments are liquidity risk, foreign currency risk and credit risk. The directors regularly review and agree policies for managing each of these risks which are summarized below.

Market risk

Market risk encompasses three types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for managing fair value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled “interest rate risk” below. The directors do not consider the Group’s exposure to price risk to be significant. The Group’s risk management is coordinated by the directors, and focuses on actively securing the Group’s short to medium term cash flows by minimizing the exposure to financial markets. The Group does not engage in the trading of financial assets for speculative purposes nor does it write options.

Credit risk

Credit risk is managed on a group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial institutions as well as credit exposure to customers including committed transactions and outstanding receivables. The group reviews its banking arrangements carefully to minimize such risks and currently has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the group as part of their internal reporting and assess outstanding receivables for ability to be repaid.

Liquidity risk

The group’s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated from operating activities and private and public offerings of equity and debt securities.

The table below summarizes the maturity profile of the Group’s financial liabilities based on contractual undiscounted payments.

	2018
$000	Less than 3 months		3 to 12 months		Total
Trade and other payables		2,631		1,010		3,641
Convertible loan notes (debt)		3		307		310
Related party payables		140		-		-
Total		2,774		1,317		4,091

Foreign currency risks

The group operates internationally although the majority of its operations are based in the United Kingdom and the majority of assets and liabilities denominated in British Pounds. It therefore is exposed to foreign exchange risk arising from exposure to various currencies primarily the Euro and US Dollar.

Due to the majority of assets being denominated in British Pounds the group has no formal policies for managing foreign currency risks.

Interest rate risk

The Group has limited exposure to interest-rate risk arising from its bank deposits. These deposit accounts are held at variable interest rates based on Allied Irish Bank base rate.

The directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result for the year or the equity position at the year-end for the years ended 31 December 2018, 2017 or 2016.

Related Party Transactions

12 Months Ended

Dec. 31, 2018

RELATED PARTY TRANSACTIONS

22.

RELATED PARTY TRANSACTIONS

Tiziana Pharma Limited is a wholly owned subsidiary of Tiziana Life Sciences plc. During the year, Tiziana Life Sciences Plc transferred $3,922k (2017: $5,146k; 2016:$3,604k) 2017: £2,566k) in total to Tiziana Pharma Limited.

Tiziana Therapeutics Inc. is a wholly owned subsidiary of Tiziana Life Sciences plc. During the year, Tiziana Life Sciences Plc transferred $1,534k (2017: $1,182k; 2016: $1,182k) to Tiziana Therapeutics Inc.

Longevia Genomics SRL. is a wholly owned subsidiary of Tiziana Life Sciences plc. During the year, Tiziana Life Sciences Plc transferred $23k (2017: $0) to Longevia Genomics SRL.

Rasna Therapeutics Inc is a related party as Kunwar Shailubhai, director of our Company, is also a director of Rasna. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of Rasna. Rasna is also party to a Shared Services agreement with Tiziana whereby the Company is charged for shared services such as the payroll and rent. As of December 31, 2018, $130k was owed to Tiziana Life Sciences PLC.

OKYO Pharma Ltd is a related party as Kunwar Shailubhai, director of our Company, is also a director of OKYO. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of OKYO. OKYO is also party to a Shared Services agreement with Tiziana whereby the Company is charged for shared services such as the payroll and rent. As of December 31, 2018, $9k was owed to Tiziana Life Sciences PLC.

Gensignia Life Sciences Inc is a related party as Kunwar Shailubhai, director of our Company, is also a director of Gensignia. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of Gensignia. As of December 31, 2018, $55k was owed to Tiziana Life Sciences PLC.

Operating Leases

12 Months Ended

Dec. 31, 2018

Operating Leases

OPERATING LEASES

23.

OPERATING LEASES

The Group leases number of office premises under operating lease. The future minimum rentals payable under non-cancellable operating leases are as follows:

	Year ended December 31,
	2018		2017		2016
	$000		$000		$000
Less than one year		423		278		266
Between one and five years		691		575		612

		1,113		853		878

Lease expenses during year ended December 30, 2018 amounted to $153k (2017: $142k; 2016: $146k).

Financial Commitments

12 Months Ended

Dec. 31, 2018

Financial Commitments

FINANCIAL COMMITMENTS

25.

FINANCIAL COMMITMENTS

The Group’s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain nature of scientific research and development and the length of time required to reach commercialization of the products of this research and development, preclinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.

●

Milciclib project research funding of approximately £1m has been committed to for 2019 and beyond. Diligence obligations are payable to BMS / Medarex should the project continue. Other payments relate to the achievement of clinical milestones or the payment of royalties.

●

Foralumab project –Future payments relate to the achievement of clinical milestones or the payment of royalties.

Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies

Basis of preparation

Basis of preparation

Going Concern

Going Concern

The Group incurred losses during the year and has net liabilities at the year end.

Basis of consolidation

Basis of consolidation

Business combination

Business combination

Segment reporting

Segment reporting

Taxation

Taxation

Foreign currency translation

Foreign currency translation

The financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis:

●

Assets and liabilities at the rate of exchange ruling at the year-end date.

●

Profit and loss account items at the average rate of exchange for the year.

License fees

License fees

Research and development

Research and development

Financial instruments

Financial instruments

Financial assets

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

(a)

Financial assets, initial recognition and measurement and subsequent measurement

(b)

Financial liabilities, initial recognition and measurement and subsequent measurement

Financial liabilities are classified as measured at amortized cost or FVTPL.

The Group’s financial liabilities include trade and other payables.

Share capital

Share capital

Ordinary shares of the company are classified as equity.

Property, IT and equipment

Property, IT and equipment

(i)

Recognition and measurement

When parts of an item of property, IT and equipment have different useful lives, they are accounted for as separate items (major components) of property, IT and equipment.

(ii)

Depreciation

Depreciation is calculated on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.

The estimated useful lives for the current period and the comparative period are as follows.

IT and equipment	3 years
Fixtures and fittings	5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the income statement.

Impairment

Impairment

Impairment of financial assets measured at amortised cost

At each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.

General approach

The general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted cash and cash and cash equivalents.

Simplified approach

The simplified approach is applied to the impairment assessment of trade receivables.

Under the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.

Non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Operating leases

Operating leases

Share based payments

Share based payments

All goods and services received in exchange for the grant of any share based payment are measured at their fair value.

Convertible loan notes

Convertible loan notes

Where there is no option to repay as cash and the interest rate is fixed

Where there is no option to repay as cash and the interest rate is variable

Remuneration of Key Management Personnel (Tables)

12 Months Ended

Dec. 31, 2018

Remuneration Of Key Management Personnel

Schedule of remuneration of key management personnel

	Year ended December 31,
$’000	2018				2017				2016
	Directors fees		Salary		Directors fees		Salary		Directors fees		Salary

W Simon		51				49				52		-
G. Cerrone		124				86				108		-
R. Dalla-Favera		26				26				27		-
K. Shailubhai (1)		-		300		10		286		27		-
		201		300		171		286		214		-

(1)

Kunwar Shailubhai became an employee of the company on May 24, 2017, at which point he ceased to be a non-executive director.

Schedule of share options were granted to directors

	Year ended December 31,
	2018		2017		2016
	Number of options		Number of options		Number of options

G. Cerrone		550,000		-		3,259,403
K. Shailubhai		6,500,000		400,000		-
L. Zanbeletti		550,000
		7,600,000		400,000		3,259,403

Share Based Payments (Tables)

12 Months Ended

Dec. 31, 2018

Share Based Payments

Schedule of share-based payment arrangements

	2018						2017						2016
	Weighted						Weighted						Weighted
	Average exercise price (cents)			Options (’000)			Average exercise price (cents)			Options (’000)			Average exercise price (cents)		Options (’000)

Outstanding at 1 January		125			10,717			90			12,449			35		7,985
Granted		104			9,500			216			668			190		4,464
Forfeited		(219	)		(1,600	)		(20	)		(2,400	)		-		-

Outstanding at 31 December		107			18,617			125			10,717			90		12,449

Exercisable at 31 December		50			5,236			57			5,011			41		4,152

Schedule of estimated a forfeiture rate of zero

	10 March 2017			30 August 2017			30 April 2018

Grant date share price	£	1.725		£	1.595		£	0.8175
Exercise share price	£	1.725		£	1.595		£	0.8175
Vesting periods		Yr1, Yr 2, Yr 3, Yr4			Yr 1, Yr 2, Yr 3, Yr4			Yr1, Yr 2, Yr 3, Yr4

Risk free rate		0.38% to 1.09	%		0.69% to 1.09	%		0.69% to 1.03	%
Expected volatility		80% to 167	%		58% to 60	%		58% to 60	%
Option life		10 years			10 years			10 years

Operating Loss (Details) - USD ($) $ in Thousands	12 Months Ended
Operating Loss (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Loss
License fee	$ 1,041	$ 662	$ 561
Depreciation	16	13	11
Foreign exchange (gain)/losses	(296)	45	215
Operating Loss	$ 761	$ 720	$ 788

Employees (Details) - USD ($) $ in Thousands	12 Months Ended
Employees (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Staff costs comprised:
Directors' salaries	$ 201	$ 211	$ 214
Wages and salaries	1,669	1,107	786
Social security costs	596	491	38
Share based payment charge	671	539	1,015
Employees, total	3,138	2,348	2,053
The average monthly number of employees, including directors, employed by the group during the year was:
Research and Development	6	6	2
Corporate and administration	5	5	4
Average monthly number of employees, including directors, employed by the group	$ 11	$ 11	$ 6

Remuneration of Key Management Personnel (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Schedule of remuneration of key management personnel [Abstract]

Directors fees

$ 201

$ 171

$ 214

Salary

300

286

W Simon [Member]

Schedule of remuneration of key management personnel [Abstract]

Directors fees

Salary

G. Cerrone [Member]

Schedule of remuneration of key management personnel [Abstract]

Directors fees

124

108

Salary

R. Dalla-Favera [Member]

Schedule of remuneration of key management personnel [Abstract]

Directors fees

Salary

K. Shailubhai [Member]

Schedule of remuneration of key management personnel [Abstract]

Directors fees

^[1]

Salary

^[1]

$ 300

$ 286

[1]	Kunwar Shailubhai became an employee of the company on May 24, 2017, at which point he ceased to be a non-executive director.

Taxation (Details) - USD ($) $ in Thousands	12 Months Ended
Taxation (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Group
Current year tax (credit)	$ (1,067)	$ (489)
Adjustments due to prior periods	(879)	(1,423)	(121)
Total tax (credit) for the period	(1,945)	(1,912)	(121)
The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as follows:
Loss before taxation	(9,939)	(10,628)	(9,891)
Loss charged at standard rate of corporation tax 19 % (2017: 19.25%; 2016: 20%)	(1,888)	(2,046)	(1,953)
Other timing differences	1,104	2,889	1,656
Expenses not deductible for taxation	176	31	297
Adjustments due to prior periods	(879)	(1,423)	(121)
Research and development claim	(459)	(1,366)
Other timing differences		3
Income tax expense (benefit)	$ (1,945)	$ (1,912)	$ (121)

Taxation (Details Textual) - USD ($) $ in Thousands	12 Months Ended
Taxation (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Taxation (Textual)
Standard rate of corporation tax	19.00%	19.25%	20.00%
Maximum percentage of surrenderable losses	14.50%
Term of R&D tax relief claims	2 years
Amount of tax losses	$ 3,928	$ 4,738	$ 3,535
United Kingdom [Member]
Taxation (Textual)
Standard rate of corporation tax	21.49%

Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Loss Per Share
(Loss) attributable to equity holders of the company ($000)	$ (7,994)	$ (9,135)	$ (10,622)
Weighted average number of ordinary shares in issue	127,553,866	106,403,903	93,592,195
Basic loss per share (cents per share)	$ (6.27)	$ (8.59)	$ (11.35)

Property, IT and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cost
Beginning	$ 46	$ 45
Additions		1
Disposals
Ending	46	46
Depreciation
Beginning	23	10
Charge in year	16	13
Ending	39	23
Net Book Value	7	23
Fixtures and fittings [Member]
Cost
Beginning	15	15
Additions
Disposals
Ending	15	15
Depreciation
Beginning	3	1
Charge in year	6	2
Ending	9	3
Net Book Value	6	12
IT equipment [Member]
Cost
Beginning	31	30
Additions		1
Disposals
Ending	31	31
Depreciation
Beginning	20	9
Charge in year	10	11
Ending	30	20
Net Book Value	$ 1	$ 11

Other Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Group
Other receivables	$ 246	$ 110
Taxation receivable	1,019	1,944
Related party receivable	25
Prepayments	42	38
Other current assets	276	292
Total	$ 1,609	$ 2,384

Investments in Subsidiaries (Details)	12 Months Ended
Investments in Subsidiaries (Details)	Dec. 31, 2018
Tiziana Pharma Limited [Member]
IfrsDisclosureOfSignificantInvestmentsInSubsidiariesLineItems [Line Items]
Name	Tiziana Pharma Limited
Principal activity	Clinical stage biotechnology company
Registered Address	3rd Floor, 11-12 St James’s Square, London, SW1Y 4LB
Percentage shareholding	100.00%
Country of incorporation	England & Wales
Tiziana Therapeutics Inc [Member]
IfrsDisclosureOfSignificantInvestmentsInSubsidiariesLineItems [Line Items]
Name	Tiziana Therapeutics, Inc.
Principal activity	Clinical stage biotechnology company
Registered Address	420 Lexington Avenue Suite 2525 New York, NY 10170
Percentage shareholding	100.00%
Country of incorporation	USA
Longevia Genomics SRL [Member]
IfrsDisclosureOfSignificantInvestmentsInSubsidiariesLineItems [Line Items]
Name	Longevia Genomics SRL
Principal activity	Biotech Discovery Company
Registered Address	Via Constantinpoli 42 09100-Cagliari (CA)
Percentage shareholding	100.00%
Country of incorporation	Italy

Share Capital (Details) - EUR (€) € in Thousands	12 Months Ended
Share Capital (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017
Euro [Member]
Schedule of share capital [Abstract]
In issue at 1 January	€ 3,752	€ 2,832
Issued for cash	232	66
Conversion of Convertible Loan notes		854
Sale of deferred shares
Conversion of warrants	45
Conversion of Loan	65
Deferred shares transferred to capital redemption reserve
In issue at 31 December	€ 4,094	€ 3,752
Ordinary Shares [Member]
Schedule of share capital [Abstract]
In issue at 1 January	125,054,805	94,393,401
Issued for cash	7,742,167	1,301,250
Conversion of Convertible Loan notes		700,000
Sale of deferred shares
Conversion of warrants	1,454,644
Conversion of Loan	2,137,625
In lieu of commission	74,577
Deferred shares transferred to capital redemption reserve
In issue at 31 December	136,463,818	125,054,805
Deferred Shares [Member]
Schedule of share capital [Abstract]
In issue at 1 January
Issued for cash
Conversion of Convertible Loan notes
Sale of deferred shares
Deferred shares transferred to capital redemption reserve
In issue at 31 December

Share Capital (Details Textual) - EUR (€) € / shares in Units, € in Thousands	1 Months Ended
	Nov. 30, 2018	Dec. 31, 2018	Oct. 31, 2018	Apr. 30, 2018	Mar. 31, 2018	Jan. 31, 2018	Dec. 17, 2017	Nov. 30, 2017	Aug. 31, 2017	Mar. 31, 2017	Dec. 31, 2013
Share Capital (Textual)
Ordinary shares par value											€ 1
Warrant holders to exercise warrants										1,789,524
Ordinary shares issued			1,515,150	1,031,250	600,000	166,667	133,333	283,333	28,455,214
Ordinary shares issued for lieu of commissions				51,563
Ordinary shares issued for shortfall of capitalized interest				23,014
Number of share issued in initial public offering	4,429,100
Number of share issued in initial public offering for extinguish of debt	2,137,625
Exercise warrants	1,400,644
Warrants description	The Company resolved to allow the holders of its warrants to exercise at reduced exercise prices in the period ending on 30 November 2018. Notification was also received from warrant holders to exercise warrants over 54,000 ordinary shares in connection with this offer.
Euro [Member]
Share Capital (Textual)
Ordinary shares par value		€ 0.03
Debt extinguish	€ 1,300

Share Based Payments (Details) - USD ($) $ in Thousands	12 Months Ended
Share Based Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Weighted Average exercise price (cents)
Outstanding at 1 January	$ 125	$ 90	$ 35
Granted	104	216	190
Forfeited	(219)	(20)
Outstanding at 31 December	107	125	90
Exercisable at 31 December	$ 50	$ 57	$ 41
Options ('000)
Outstanding at 1 January	10,717,000	12,449,000	7,985,000
Granted	9,500,000	668,000	4,464,000
Forfeited	(1,600,000)	(2,400,000)
Outstanding at 31 December	18,617,000	10,717,000	12,449,000
Exercisable at 31 December	5,236,000	5,011,000	4,152,000

Share Based Payments (Details 1)	12 Months Ended
Share Based Payments (Details 1)	Dec. 31, 2018 € / shares
10 March 2017 [Member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Grant date share price	€ 1.725
Exercise share price	€ 1.725
Vesting periods	Yr1, Yr 2, Yr 3, Yr4
Option life	10 years
10 March 2017 [Member] \| Bottom of range [member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Risk free rate	0.38%
Expected volatility	80.00%
10 March 2017 [Member] \| Top of range [member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Risk free rate	1.09%
Expected volatility	167.00%
30 August 2017 [Member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Grant date share price	€ 1.595
Exercise share price	€ 1.595
Vesting periods	Yr 1, Yr 2, Yr 3, Yr4
Option life	10 years
30 August 2017 [Member] \| Bottom of range [member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Risk free rate	0.69%
Expected volatility	58.00%
30 August 2017 [Member] \| Top of range [member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Risk free rate	1.09%
Expected volatility	60.00%
30 April 2018 [Member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Grant date share price	€ 0.8175
Exercise share price	€ 0.8175
Vesting periods	Yr1, Yr 2, Yr 3, Yr4
Option life	10 years
30 April 2018 [Member] \| Bottom of range [member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Risk free rate	0.69%
Expected volatility	58.00%
30 April 2018 [Member] \| Top of range [member]
IfrsDisclosureofShareBasedPaymentsLineItems [Line Items]
Risk free rate	1.03%
Expected volatility	60.00%

Share Based Payments (Details Textual) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2018
Share Based Payments (Textual)
Fair value of the share option instruments		$ 6,217	$ 2,305	$ 6,591
Fair value of the warrant instruments	$ 1,397,662	340,501
Share-based payment	$ 89,431	$ 120,441	$ 156,424
Expected term of the awards		15 years

Financial Instruments (Details) $ in Thousands	Dec. 31, 2018 USD ($)
IfrsFinancialInstrumentsItemsLineItems [Line Items]
Trade and other payables	$ 3,641
Convertible loan notes (debt)	310
Related party payables
Total	4,091
Less then 3 months [Member]
IfrsFinancialInstrumentsItemsLineItems [Line Items]
Trade and other payables	2,631
Convertible loan notes (debt)	3
Related party payables	140
Total	2,774
3 to 12 Months [Member]
IfrsFinancialInstrumentsItemsLineItems [Line Items]
Trade and other payables	1,010
Convertible loan notes (debt)	307
Related party payables
Total	$ 1,317

Trade and Other Payables (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Trade and other payables [abstract]
Trade payables	$ 3,641	$ 3,738	$ 1,496
Accruals	2,310	683	369
Convertible loan note liability	310	316	278
Related party payable	140	12
Total	$ 6,401	$ 4,749	$ 2,143

Related Party Transactions (Details) € in Thousands, $ in Thousands	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2016 USD ($)
OKYO Pharma Ltd [Member]
IfrsRelatedPartyTransactionsLineItems [Line Items]
Payroll and rent charged	$ 130
Rasna Therapeutics Inc [Member]
IfrsRelatedPartyTransactionsLineItems [Line Items]
Payroll and rent charged	9
Gensignia Lifesceinecs Inc [Member]
IfrsRelatedPartyTransactionsLineItems [Line Items]
Payroll and rent charged	55
Subsidiaries [Member] \| Tiziana Pharma Limited [Member]
IfrsRelatedPartyTransactionsLineItems [Line Items]
Amounts payable to related party	3,922	$ 5,146		$ 3,640
Subsidiaries [Member] \| Tiziana Pharma Limited [Member] \| Euro [Member]
IfrsRelatedPartyTransactionsLineItems [Line Items]
Amounts payable to related party \| €			€ 2,566
Subsidiaries [Member] \| Tiziana Therapeutics Inc [Member]
IfrsRelatedPartyTransactionsLineItems [Line Items]
Amounts payable to related party	1,534	1,182		$ 1,182
Subsidiaries [Member] \| Longevia Genomics SRL [Member]
IfrsRelatedPartyTransactionsLineItems [Line Items]
Payroll and rent charged	$ 23	$ 0

Accounting Policies (Details)	12 Months Ended
Accounting Policies (Details)	Dec. 31, 2018
IT and equipment [Member]
IfrsDisclosureOfAccountingPoliciesLineItems [Line Items]
Estimated useful lives	3 years
Fixtures and fittings [Member]
IfrsDisclosureOfAccountingPoliciesLineItems [Line Items]
Estimated useful lives	5 years

Accounting Policies (Details Textual)	Dec. 31, 2013 € / shares
Accounting Policies
Issue of ordinary share capital	€ 1

Other Assets (Details) - Jun. 30, 2016 € in Thousands, $ in Thousands	USD ($)	EUR (€)
IfrsOtherAssetsLineItems [Line Items]
Purchase of data repository of DNA \| $	$ 268
Euro [Member]
IfrsOtherAssetsLineItems [Line Items]
Purchase of data repository of DNA \| €		€ 258

Convertible Loan Notes (Details Textual)	12 Months Ended
Convertible Loan Notes (Details Textual)	Dec. 31, 2018
Convertible Loan Notes (Textual)
Description of convertible loan notes	From the date of the reverse acquisition a convertible loan note of $247k was in existence as detailed in the Admission Document dated 31 March 2014. Proceeds of the subscriptions for the notes are to be used exclusively to finance the company's on-going working capital requirements. The terms of the loan note are that the loan notes, plus accrued interest at a rate of 4 per cent above Bank of England base rate per annum, will convert into ordinary shares in the company at a price of £0.10 per share at the election of Planwise any time after the second anniversary of the readmission to AIM on 24 April 2014.

Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
OperatingLeasesLineItems [Line Items]
Future minimum rentals payable under non-cancellable operating leases	$ 1,113	$ 853	$ 878
Less than one year [Member]
OperatingLeasesLineItems [Line Items]
Future minimum rentals payable under non-cancellable operating leases	423	278	266
Between one and five years [Member]
OperatingLeasesLineItems [Line Items]
Future minimum rentals payable under non-cancellable operating leases	$ 691	$ 575	$ 612

Finance Costs (Details) - USD ($) $ in Thousands	12 Months Ended
Finance Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Group
Finance charge accrued on convertible loan notes (recognized as debt)	$ 12	$ 12	$ 12
Total finance costs	$ 12	$ 12	$ 12

Convertible Loan Notes (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Convertible Loan Notes
Convertible loan notes issued	$ 290	$ 278	$ 247
Accrued interest	11	12	31
Planwise Convertible Loan Note	$ 302	$ 290	$ 278

Reserves (Details) - USD ($) $ in Thousands	12 Months Ended
Reserves (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2016
Notes to Financial Statements
Capital reduction reserve	$ 41,300	$ (1,999)

Operating Leases (Details Textual) - USD ($) $ in Thousands	12 Months Ended
Operating Leases (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Leases (Textual)
Lease expenses	$ 153	$ 142	$ 146